Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform. Its product candidates include PLX-PAD, which is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, as well as contract development and manufacturing organization (CDMO) services for pharmaceutical and biotechnology companies under the PluriCDMO division, and AgTech. It has a collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.…
Pluri: Fiscal Q1 Earnings Snapshot
Pluri (NASDAQ: PLUR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 92 employees.
The shares were at 0.9400 USD on 20 November 2026, down 77.3% over 52 weeks. Its 52-week range is 0.8500 USD to 4.870 USD: the price is 80.7% below the high and 10.6% above the low.
Its market capitalisation is 13.51M USD.
Pluri reports return on equity of 103.4% and revenue up 140.2% year over year.
Its debt exceeds its cash by 26.80M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.